检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:Francisco J.Esteva Shabnam Jaffer
机构地区:[1]Division of Hematology and Medical Oncology,Lenox Hill Hospital,New York,NY 10065,USA [2]Department of Pathology,Lenox Hill Hospital,New York,NY 10065,USA
出 处:《Journal of Cancer Metastasis and Treatment》2023年第1期541-547,共7页癌症转移与治疗(英文版)
摘 要:The identification of HER2-low metastatic breast cancer as a novel subgroup with therapeutic implications underscores the intricacies in breast cancer classification.This subset,comprising 45%-60%of breast cancer cases,presents a challenge due to its heterogeneous nature,characterized by varying HER2 protein expression levels.This heterogeneity complicates diagnosis and treatment decisions.The advent of trastuzumab deruxtecan(T-DXd),a second-generation antibody-drug conjugate(ADC),instills renewed hope for HER2-low breast cancer patients,having demonstrated effectiveness in clinical trials.The article also explores the evolution of HER2 testing guidelines,notably the 2023 ASCO/CAP guidelines that acknowledge the potential benefits of HER2-targeted therapies for this subgroup.In summary,this article emphasizes the significance of collaborative efforts between Pathologists and Oncologists in the era of precision medicine.It also highlights the potential for innovative,tailored therapies for HER2-low breast cancer,promising enhanced treatment outcomes and a broader range of therapeutic options.
关 键 词:HER2-low breast cancer HETEROGENEITY trastuzumab deruxtecan(T-DXd) HER2 testing guidelines precision medicine therapeutic strategies IMMUNOHISTOCHEMISTRY in situ hybridization
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222